Lv21
158 积分 2021-08-17 加入
PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy
1小时前
待确认
Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy
1小时前
已完结
Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms
2小时前
已完结
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology
7天前
已完结
TGF-β builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1+ macrophages
1个月前
已完结
TGFβ biology in cancer progression and immunotherapy
1个月前
已完结
T cell exclusion, immune privilege, and the tumor microenvironment
1个月前
已完结
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma
1个月前
已完结
Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
1个月前
已完结
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
1个月前
已完结
皖公网安备34019202002308
